IndustryFebruary 2026
Ablynx's Cablivi Crosses $1B Annual Sales — Market Validation for the VHH Modality
Sanofi's caplacizumab (Cablivi), the first FDA-approved VHH nanobody, has crossed the $1 billion annual revenue milestone, proving that single-domain antibodies are not just a research curiosity but a commercially viable therapeutic modality.
JFInnova Perspective
Cablivi proves the VHH modality works at scale. JFIN-0001 inherits the same manufacturing advantages (E. coli/Pichia expression, single disulfide bond, high stability) while targeting a completely different axis — MIF/CD74 in neuroinflammation — an untapped $8B+ market.
Cablivi VHH nanobody billion revenue